Showing 841 - 850 of 854 for "Pharmaceutical" with applied filters
Filters:
23 November 2018 by Ilya Kazi
Ilya Kazi and Miranda Kent of Mathys & Squire analyse the changes to the EPO’s opposition procedure and suggest ways in which businesses can align their strategy with the current legal tools available
01 September 2018 by Managing Intellectual Property
Resolution Chemicals v AstraZeneca B.V. and Shionogi (Supreme Court of The Netherlands, The Hague, June 8 2018) deals with the extent of the protection that is conferred by patent EP0521471 (EP 471), for rosuvastatin, a new cholesterol inhibitor.
01 September 2018 by Spoor & Fisher
On June 28 2018 the Zimbabwean authorities published a document entitled the Zimbabwe Intellectual Property Policy and Implementation Strategy.
01 September 2018 by Jing He
On June 1 2018, the Supreme People’s Court of China (SPC) issued the draft judicial interpretation on patent validity and examination cases for public comments
31 August 2018 by Managing Intellectual Property
The decision of the Full Federal Court in GlaxoSmithKline (GSK) Consumer Healthcare Investments (Ireland) (No 2) Limited v Generic Partners Pty Limited (2018) FCAFC 71 (May 10 2018) indicates that a mistake in a claim cannot be ignored even where the skilled person understands that a mistake has been made.
02 July 2018 by Sybille Pfender
At the end of April 2018, Advocate General (AG) Wathelet handed down an advisory opinion regarding the first of three recent referrals to the CJEU (C-121/17). This concerns the interpretation of Article 3(a) of Regulation (EC) No 469/2009.
01 June 2018 by Henri van Kalkeren
Cialis® is a pharmaceutical product for the treatment of erectile dysfunction developed by Lilly ICOS, a joint venture of ICOS Corporation and Eli Lilly and Company.
01 June 2018 by Managing Intellectual Property
A common dilemma for inventors and applicants before the European Patent Office is whether an invention is sufficiently mature for a patent application to be filed.
01 June 2018 by Jing He
China announced a huge government reshuffle programme. The sweeping government restructuring programme was said to be the largest reform since the end of the Mao Zedong era in the 1970s
19 May 2018 by Isabella Cardozo
Isabella Cardozo, Hannah Fernandes and Rafael Rocha of Daniel Legal and IP Strategy evaluate the benefits of judicial appeals and stress the importance of agreements which are effective in Brazil
